Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

danaher corp. - DHR

DHR

Close Chg Chg %
190.05 -2.93 -1.54%

Closed Market

187.12

-2.93 (1.54%)

Volume: 5.27M

Last Updated:

Mar 25, 2026, 3:59 PM EDT

Trade Now

Company Overview: danaher corp. - DHR

DHR Key Data

Open

$192.92

 Day Range

184.99 - 192.96

52 Week Range

171.01 - 242.75

 Market Cap

$134.43B

Shares Outstanding

707.14M

 Public Float

644.47M

Beta

0.93

 Rev. Per Employee

N/A

P/E Ratio

37.67

 EPS

$5.08

Yield

67.33%

 Dividend

$0.40

EX-DIVIDEND DATE

Mar 27, 2026

 SHORT INTEREST

N/A

AVERAGE VOLUME

4.04M

  

DHR Performance

1 Week
 
 0.40%
 
1 Month
 
 -9.75%
 
3 Months
 
 -17.46%
 
1 Year
 
 -7.65%
 
5 Years
 
 -4.83%
 

DHR Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 27
Full Ratings ➔

About danaher corp. - DHR

Danaher Corp. engages in the design, manufacture, and marketing of professional, medical, industrial, and commercial products and services. It operates through the following segments: Biotechnology, Life Sciences, and Diagnostics. The Biotechnology segment includes bioprocessing, discovery, and medical businesses and offers a range of tools, consumables, and services. The Life Sciences segment offers a range of instruments and consumables to study the basic building blocks of life, including DNA and RNA. The Diagnostics segment offers clinical instruments, reagents, consumables, software, and services used to diagnose disease and make treatment decisions. The company was founded by Steven M. Rales and Mitchell P. Rales in 1984 and is headquartered in Washington, DC.

DHR At a Glance

Danaher Corp.
2200 Pennsylvania Avenue North West
Washington, District of Columbia 20037-1701
Phone 1-202-828-0850 Revenue 24.57B
Industry Medical Specialties Net Income 3.61B
Sector Health Technology 2025 Sales Growth 2.903%
Fiscal Year-end 12 / 2026 Employees 60,000
View SEC Filings

DHR Valuation

P/E Current 37.648
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 45.359
Price to Sales Ratio 6.672
Price to Book Ratio 3.08
Price to Cash Flow Ratio 25.55
Enterprise Value to EBITDA 23.252
Enterprise Value to Sales 7.287
Total Debt to Enterprise Value 0.11

DHR Efficiency

Revenue/Employee 409,466.667
Income Per Employee 60,233.333
Receivables Turnover 5.012
Total Asset Turnover 0.305

DHR Liquidity

Current Ratio 1.874
Quick Ratio 1.508
Cash Ratio 0.678

DHR Profitability

Gross Margin 59.232
Operating Margin 21.377
Pretax Margin 17.23
Net Margin 14.71
Return on Assets 4.472
Return on Equity 7.053
Return on Total Capital 4.984
Return on Invested Capital 5.216

DHR Capital Structure

Total Debt to Total Equity 37.492
Total Debt to Total Capital 27.268
Total Debt to Total Assets 23.598
Long-Term Debt to Equity 37.109
Long-Term Debt to Total Capital 26.99
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Danaher Corp. - DHR

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
31.47B 23.89B 23.88B 24.57B
Sales Growth
+6.85% -24.09% -0.06% +2.90%
Cost of Goods Sold (COGS) incl D&A
12.52B 9.86B 9.67B 10.02B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
2.22B 2.17B 2.35B 2.45B
Depreciation
738.00M 675.00M 721.00M 750.00M
Amortization of Intangibles
1.48B 1.49B 1.63B 1.70B
COGS Growth
+8.88% -21.29% -1.90% +3.59%
Gross Income
18.95B 14.03B 14.21B 14.55B
Gross Income Growth
+5.55% -25.94% +1.23% +2.44%
Gross Profit Margin
+60.21% +58.74% +59.50% +59.23%
2022 2023 2024 2025 5-year trend
SG&A Expense
10.25B 8.76B 9.02B 9.30B
Research & Development
1.75B 1.50B 1.58B 1.60B
Other SG&A
8.51B 7.25B 7.44B 7.70B
SGA Growth
+3.53% -14.60% +3.05% +3.08%
Other Operating Expense
- - - -
-
Unusual Expense
403.00M 348.00M 534.00M 670.00M
EBIT after Unusual Expense
8.29B 4.93B 4.65B 4.58B
Non Operating Income/Expense
212.00M 402.00M 274.00M (84.00M)
Non-Operating Interest Income
41.00M 303.00M 117.00M 30.00M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
214.00M 289.00M 278.00M 265.00M
Interest Expense Growth
-11.20% +35.05% -3.81% -4.68%
Gross Interest Expense
214.00M 289.00M 278.00M 265.00M
Interest Capitalized
- - - -
-
Pretax Income
8.29B 5.04B 4.65B 4.23B
Pretax Income Growth
+9.13% -39.17% -7.89% -8.89%
Pretax Margin
+26.35% +21.11% +19.46% +17.23%
Income Tax
1.08B 823.00M 747.00M 633.00M
Income Tax - Current - Domestic
413.00M 756.00M 301.00M 298.00M
Income Tax - Current - Foreign
1.23B 1.27B 929.00M 775.00M
Income Tax - Deferred - Domestic
(400.00M) (866.00M) (342.00M) (307.00M)
Income Tax - Deferred - Foreign
(159.00M) (338.00M) (141.00M) (133.00M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
7.21B 4.22B 3.90B 3.60B
Minority Interest Expense
- - - -
-
Net Income
7.21B 4.22B 3.90B 3.60B
Net Income Growth
+13.58% -41.45% -7.63% -7.67%
Net Margin Growth
+22.91% +17.67% +16.33% +14.65%
Extraordinaries & Discontinued Operations
- - 543.00M 14.00M
-
Discontinued Operations
- - 543.00M 14.00M
-
Net Income After Extraordinaries
7.21B 4.76B 3.90B 3.61B
Preferred Dividends
- - 106.00M 21.00M
-
Net Income Available to Common
7.10B 4.74B 3.90B 3.61B
EPS (Basic)
9.7959 6.4399 5.3338 5.0709
EPS (Basic) Growth
+11.66% -34.26% -17.18% -4.93%
Basic Shares Outstanding
725.10M 736.50M 731.00M 712.70M
EPS (Diluted)
9.6636 6.3827 5.2889 5.0468
EPS (Diluted) Growth
+12.18% -33.95% -17.14% -4.58%
Diluted Shares Outstanding
737.10M 743.10M 737.20M 716.10M
EBITDA
10.92B 7.45B 7.54B 7.70B
EBITDA Growth
+6.86% -31.82% +1.22% +2.16%
EBITDA Margin
+34.70% +31.16% +31.56% +31.34%

Snapshot

Average Recommendation BUY Average Target Price 264.19
Number of Ratings 27 Current Quarters Estimate 1.938
FY Report Date 03 / 2026 Current Year's Estimate 8.411
Last Quarter’s Earnings 2.23 Median PE on CY Estimate N/A
Year Ago Earnings 7.80 Next Fiscal Year Estimate 9.107
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 21 21 24 24
Mean Estimate 1.94 1.88 8.41 9.11
High Estimates 1.96 1.99 8.51 9.42
Low Estimate 1.92 1.80 8.35 8.98
Coefficient of Variance 0.64 2.10 0.47 1.23

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 19 19 21
OVERWEIGHT 4 4 4
HOLD 4 4 4
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Danaher Corp. - DHR

Date Name Shares Transaction Value
Mar 5, 2026 Julie Sawyer Montgomery Executive Vice President 16,681 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 5, 2026 Georgeann F. Couchara SVP, Human Resources 8,572 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $210.64 per share 1,805,606.08
Mar 5, 2026 Julie Sawyer Montgomery Executive Vice President 22,221 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $210.64 per share 4,680,631.44
Mar 5, 2026 Georgeann F. Couchara SVP, Human Resources 12,831 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 5, 2026 Julie Sawyer Montgomery Executive Vice President 23,301 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 5, 2026 Georgeann F. Couchara SVP, Human Resources 8,685 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 5, 2026 Robert Bradley Gray SVP Strategic Development 7,699 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 5, 2026 Robert Bradley Gray SVP Strategic Development 14,463 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Nov 20, 2025 Jonathan B. Leiken SVP- General Counsel 10,172 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Nov 20, 2025 Greg Milosevich Executive Vice President 4,420 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $221.21 per share 977,748.20
Nov 20, 2025 Jonathan B. Leiken SVP- General Counsel 26,767 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 29, 2025 A. Shane Sanders Director 2,350 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 29, 2025 Raymond C. Stevens Director 6,728 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 29, 2025 Teri L. List-Stoll Director 7,621 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 29, 2025 Elias A. Zerhouni Director 17,809 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 29, 2025 Feroz Dewan Director 1,706 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 29, 2025 Linda Hefner Filler Director 8,890 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 29, 2025 Alan G. Spoon Director 30,172 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 20, 2025 Charles W. Lamanna Director 1,478 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 20, 2025 Elias A. Zerhouni Director 1,478 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Danaher Corp. in the News